Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04592874 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
A Phase 2 study, sponsored by Alector.
- Completed
- Registry status
- Phase 2
- Development phase
- 356
- Enrollment target
NCT04592874 is a Phase 2 study that has completed, run by Alector. The registered enrollment target is 356 participants.
The verdict
NCT04592874, a Phase 2 study, has completed, sponsored by Alector.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 356 participants
- Enrollment target
Study Summary
A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.
Interventions
- DRUG Placebo
- DRUG AL002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2021-01-22 |
| Est. Completion | 2024-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04592874
The ClinicalTrials.gov registry entry for NCT04592874 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 356 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alector, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04592874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04592874 about?
NCT04592874 is a clinical study titled "A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease". A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.
What is the current status of trial NCT04592874?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 356 participants. The study started on 2021-01-22. Estimated completion is 2024-09-12.
What interventions are being tested in trial NCT04592874?
The interventions under investigation include: Placebo (DRUG), AL002 (DRUG).
Who is sponsoring clinical trial NCT04592874?
This trial is sponsored by Alector, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.